Agonist antibodies that bind to the LT-beta receptor, thereby modulating adiposity-associated phenotypes, and their use in therapy

摘要

Use of a lymphotoxin beta receptor activating agent, preferably a lymphotoxin beta-receptor antibody (anti LT-beta -R-AB), for preparing a pharmaceutical composition for the prevention and/or treatment of obesity, obesity associated diabetes (type II), metabolic syndrome, and/or other obesity related disorders, is new. Independent claims are also included for: (1) a substance comprising at least one of the activating epitopes of LT-beta -R; (2) a pharmaceutical composition comprising a beta -receptor activating agent or the substance above; (3) use of the substance comprising an activating epitope of LT-beta -R for the preparation of an activating LT-beta -R antibody, or for the preparation of a vaccine for the prevention and/or treatment of obesity, associated diabetes (type II), metabolic syndrome, and/or other obesity associated disorders; and (4) a method for the selection of a LT-beta -R activating agent. ACTIVITY : Anorectic; Antidiabetic; Metabolic. C57BL6/J mice were divided into treatment group and a control group. The treatment group was injected a rat-anti-mouse LT-beta -R IgG2a (treatment group), the control group was injected a corresponding isotype control antibody (rat IgG2a). The mice were fed a normal chow diet, and food and acidified water were given ad libitum, for six weeks. After a 4-hour fast, mice were weighed, and then anaesthetized with FFM (fentanyl citrate, fluanisone, midazolam). Results showed a significant decrease in adipose tissue mass in the treatment compared to the control group. MECHANISM OF ACTION : Lymphotoxin-Beta-Receptor-Agonist.